Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation, has made a new investment in SeraGene Therapeutics, a biotechnology company developing RNA-based and nanomedicine therapies to transform the treatment landscape for blood coagulation disorders.
SeraGene Therapeutics emerged from two of North America’s leading blood research institutions, the Versiti Blood Research Institute in Wisconsin and the Center for Blood Research at the University of British Columbia. Supported by Canada’s Nanomedicines Innovation Network, the company is headquartered in Vancouver and has rapidly gained recognition for its scientific achievements. In the past two years, SeraGene was named a Company to Watch at the Life Sciences BC Awards, earned the Coup de Coeur prize at Sweet Pharma Day, and became a finalist for the Eli Lilly Grand Challenge.
The company’s technology centers on RNA therapies that can either suppress plasminogen to stabilize clot formation or increase the expression of genes required for coagulation. These therapies are delivered via advanced lipid nanoparticles engineered to target liver cells with high precision. This approach is designed to reduce the need for frequent dosing and improve accuracy in gene modulation, offering promising outcomes for individuals living with inherited or rare coagulation disorders, including women disproportionately affected by conditions such as von Willebrand disease.
The investment from Pathway to Cures adds to the support SeraGene has received from several leading life science investors. Early backers include Hextwo Capital, Adage Capital Partners, Blue Owl Healthcare Opportunities, Boxer Capital, Commodore Capital, Deep Track Capital, Foresite Capital, and Logos Capital.
Pathway to Cures operates as a venture philanthropy fund that accelerates solutions for inherited blood and bleeding disorders. By reinvesting returns into future opportunities, the organization seeks to build a sustainable portfolio of therapeutic innovations, strengthen biotech development pipelines, and deepen the National Bleeding Disorders Foundation’s role in advancing scientific progress.
KEY QUOTES
“The potential for SeraGene’s innovative therapies to improve lives in our bleeding disorders community, especially for women and girls, makes this an exciting partnership for us.”
“We are delighted to expand our portfolio with this strategic investment and impact the treatment of bleeding disorders including von Willebrand disease (VMD) with a focus on women’s health.”
Teri Willey, Managing Director and Officer, NBDF’s Pathway to Cures Venture Fund
